Current research priorities in chronic fatigue syndrome/myalgic encephalomyelitis: Disease mechanisms, a diagnostic test and specific treatments

Journal of Clinical Pathology

Volumn 60, Issue 2, 2007, Pages 113-116

  Kerr, J R ^a   Christian, P ^b   Hodgetts, A ^b   Langford, P R ^b   Devanur, L D ^a   Petty, R ^a   Burke, B ^a   Sinclair, L I ^c   Richards, S C M ^d   Montgomery, J ^d   McDermott, C R ^d   Harrison, T J ^e   Kellam, P ^e   Nutt, D J ^c   Holgate, S T ^f   Honeybourne, D ^g   Smith, A P ^h   Thomas, M ^h   Ayres, J G ⁱ   Main, J ^b   Daymond, T ^j   Bansal, A ^k   Puri, B K ^l   Morgan, R ^b   Peveler, R C ^f   Axford, J S ^a   Weir, W ^m   Enlander, D ⁿ   Chia, J K ^o   more..

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ UNIVERSITY OF ABERDEEN   (United Kingdom)

^j UNIVERSITY OF SUNDERLAND   (United Kingdom)

^k ST HELIER HOSPITAL   (United Kingdom)

^l HAMMERSMITH HOSPITAL   (United Kingdom)

^m Hammersmith Hospital ^*  (United Kingdom)

ⁿ New York Gastroenterology Associates   (United States)

^o ID Med   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; DIAGNOSTIC TEST; GENE EXPRESSION; HUMAN; MASS SPECTROMETRY; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW;

FATIGUE SYNDROME, CHRONIC; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON-BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846977013     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.042374     Document Type: Review

References (23)

1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994;121:953- 9.
2. Report of the CFS/ME Working Group. Department of Health, January 2002. Report to the Chief Medical Officer of an Independent Working group.
3. Afari N, Buchwald D. Chronic fatigue syndrome: a review. Am J Psychiatry 2003;160:221-36.
4. Kaushik N, Fear D, Richards SC, et al. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol 2005;58:826-32.
5. Vernon SD, Unger ER, Dimulescu IM, et al. Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue syndrome. Dis Markers 2002;18:193-9.
6. Powell R, Ren J, Lewith G, et al. Identification of novel expressed sequences, upregulated in the leucocytes of chronic fatigue syndrome patients. Clin Exp Allergy 2003;33:1450-6.
7. Grans H, Nilsson P, Evengard B. Gene expression profiling in the chronic fatigue syndrome. J Intern Med 2005;258:388-90.
8. Grans H, Nilsson M, Dahlman-Wright K, et al. Reduced levels of oestrogen receptor β mRNA in Swedish patients with chronic fatigue syndrome. J Clin Pathol. Published Online First: 26 May 2006, doi:10.1136/jcp.2005.035956.
9. Whistler T, Unger ER, Nisenbaum R, et al. Integration of gene expression, clinical, and epidemiologic data to characterize chronic fatigue syndrome. J Transl Med 2003;1:10.
10. Whistler T, Jones JF, Unger ER, et al. Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects. BMC Physiol 2005;5:5.
11. Whistler T, Taylor R, Craddock RC, et al. Gene expression correlates of unexplained fatigue. Pharmacogenomics 2006;7:395- 405.
12. Gow JW, Cannon C, Behan WMH, et al. Whole-genome (33,000 genes) affymetrix DNA microarray analysis of gene expression in chronic fatigue syndrome (abstract S7-03/P2-19). International Conference on Fatigue Science, February 2005, Karuizawa, Japan.
13. Carmel L, Efroni S, White PD, et al. Gene expression profile of empirically delineated classes of unexplained chronic fatigue. Pharmacogenomics 2006;7:375-86.
14. Broderick G, Craddock RC, Whistler T, et al. Identifying illness parameters in fatiguing syndromes using classical projection methods. Pharmacogenomics 2006;7:407-19.
15. Craddock RC, Taylor R, Broderick G, et al. Exploration of statistical dependence between illness parameters using the entropy correlation coefficient. Pharmacogenomics 2006;7:421-8.
16. Fang H, Xie Q, Boneva R, et al. Gene expression profile exploration of a large datoset on chronic fatigue syndrome. Pharmacogenomics 2006;7:429-40.
17. Fostel J, Boneva R, Lloyd A. Exploration of the gene expression correlates of chronic unexplained fatigue using factor analysis. Pharmacogenomics 2006;7:441-54.
18. Lin SM, Devakumar J, Kibbe WA. Improved prediction of treatment response using microarrays and existing biological knowledge. Pharmacogenomics 2006;7:495-501.
19. Waltman P, Pearlman A, Mishra B. Interpreter of maladies: redescription mining applied to biomedical data analysis [review]. Pharmacogenomics 2006;7:503-9.
20. Shoemaker J. Statistical challenges with gene expression studies. Pharmacogenomics 2006;7:511-19.
21. Arnason BG. Long-term experience with interferon beta-1b (Betaferon) in multiple sclerosis. J Neurol 2005;252(Suppl 3):iii28-33.
22. Heesen C, Nawrath L, Reich C, et al. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry 2006;77:34-9.
23. Lamprecht K, et al. Pilot study of etanercept treatment in patients with chronic fatigue syndrome. Meeting of the American Association of Chronic Fatigue Syndrome (AACFS), Seattle, 2001. http://cfs-news.org/ accfs-ol.htm.